MIMEDX GROUP, INC.
No enriched coverage for $MDXG in the last 7 days.
No SEC Form 4 filings for $MDXG in the last 30 days.
MiMedx Group agreed to acquire Sanara MedTech in a cash-and-stock deal valued at about $350 million enterprise value, per MiMedx’s July 30 release. Sanara shareholders will receive $33 cash plus 0.4735 MiMedx shares per share, totaling $35 per share. The stock value uses MiMedx’s $4.22 average price. Deal expected to close by year-end, subject to approvals; combined 2027 revenue projected above $400 million.
Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX’s Strategic Priority to Expand Surgical Footprint, Nearly Doubling Surgical Revenue Immediately Accretive to Revenue Growth, Gross Margin and Adjusted EBITDA Margin Anticipates Over $20 Million in Run-Rate Cost Synergies Conference Call to Discuss Transaction Alongside MIMEDX’s Second Quarter 2026 Operating and Financial Results Today at 4:30pm...
MiMed Group Inc. (MDXG) agreed to acquire Sanara MedTech Inc. (SMTI) for $35 per share, about $350 million. Sanara’s products include CellerateRX and BIASURGE, and it plans a 2027 launch of OsStic BioAdhesive, FDA Breakthrough-designated. MiMedx projects combined 2027 revenue over $400 million and adjusted EBITDA margins above 20%, with $20M+ synergies. SMTI is up 12.1% to $33.91.
Recent MDXG coverage spans mergers & acquisitions, earnings and corporate actions.
Deal terms and projected 2027 revenue expansion create a near-term repricing risk for MDXG tied to deal certainty and closing timeline.
Deal terms and financing are likely to drive near-term repricing for MDXG on accretion, synergy, and closing-risk expectations.
Deal terms and integration targets create a near-term M&A arbitrage and longer-term fundamental re-rating setup for MDXG.
The earnings snapshot provides fresh quarterly results and a full-year revenue range that can reset near-term expectations.
Acquisition announcement can drive re-rating and integration expectations, but dilution and deal economics matter.
alphai scores every news story that mentions MDXG with an AI model for sentiment and relevance, and aggregates insider trades from MIMEDX GROUP, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MiMedx Group agreed to acquire Sanara MedTech in a cash-and-stock deal valued at about $350 million enterprise value, per MiMedx’s July 30 release. Sanara shareholders will receive $33 cash plus 0.4735 MiMedx shares per share, totaling $35 per share. The stock value uses MiMedx’s $4.22 average price. Deal expected to close by year-end, subject to approvals; combined 2027 revenue projected above $400 million.
4 min readTransformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX’s Strategic Priority to Expand Surgical Footprint, Nearly Doubling Surgical Revenue Immediately Accretive to Revenue Growth, Gross Margin and Adjusted EBITDA Margin Anticipates Over $20 Million in Run-Rate Cost Synergies Conference Call to Discuss Transaction Alongside MIMEDX’s Second Quarter 2026 Operating and Financial Results Today at 4:30pm...
4 min readMiMed Group Inc. (MDXG) agreed to acquire Sanara MedTech Inc. (SMTI) for $35 per share, about $350 million. Sanara’s products include CellerateRX and BIASURGE, and it plans a 2027 launch of OsStic BioAdhesive, FDA Breakthrough-designated. MiMedx projects combined 2027 revenue over $400 million and adjusted EBITDA margins above 20%, with $20M+ synergies. SMTI is up 12.1% to $33.91.
4 min readMiMedx Group Inc. (MDXG) reported a Q2 loss of $14.8 million, or 10 cents per share. Adjusted for non-recurring items, it posted a 5 cents per share loss. Revenue was $64.4 million. The company expects full-year revenue of $260 million to $290 million.
2 min readBiotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.
3 min readMIMEDX GROUP, INC. (MDXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mdxg-q22026pressreleasevf4.htm EX-99.1 Document MIMEDX Announces Second Quarter 2026 Operating & Financial Results Reports Second Quarter Net Sales of $64 Million Reiterates Full Year Financial Outlook on a Standalone Basis Announces Plans to Acquire Sanara MedTech Mana
6 min readMIMEDX GROUP, INC. (MDXG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ex-21agreementplanofmerger.htm EX-2.1 Document Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER dated as of July 29, 2026 among SANARA MEDTECH INC., MIMEDX GROUP, INC. and MUSTANG MERGER SUB, INC. TABLE OF CONTENTS Section 1.1 Definitions 1 Section 1.2 Other De
3 min readMIMEDX GROUP, INC. (MDXG) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-3.2 2 bylaws-amendedrestated2026.htm EX-3.2 Document Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF MIMEDX GROUP, INC. ARTICLE I Corporate Offices Section 1. Principal and Registered Offices . The principal office of MiMedx Group, Inc. (the “ Corporation ”) shall be located at suc
2 min readMiMedx Group Inc. (MDXG) reported disappointing Q1 2026 results, missing both earnings and revenue forecasts, leading to a 1.76% stock price drop in aftermarket trading. The company posted an EPS of -$0.05 against an anticipated -$0.01 and revenue of $59 million, falling short of the $69.18 million expectation. This downturn is attributed primarily to significant disruptions in the wound care market due to Medicare reimbursement reforms, although the surgical business showed a 13% growth.
4 min readMIMEDX Group (NASDAQ: MDXG) announced its sponsorship and participation in two major wound care conferences: SAWC Spring 2026 and the Diabetic Limb Salvage (DLS) 2026 Conference. The company will present scientific data through symposia, poster, and oral presentations, showcasing its peptide-based and placental allograft wound care technologies. This engagement highlights MIMEDX's commitment to advancing wound care science, particularly with its stock trading near its 52-week low.
3 min read
